ArticleBMC chemistry2025

Discovery of novel FABP1 inhibitors for the treatment of metabolic dysfunction-associated steatohepatitis and hepatic fibrosis.

Zongtao Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.